Literature DB >> 3082546

In-vitro cell-mediated cytotoxicity for autologous liver cells in chronic non-A, non-B hepatitis.

M Mondelli, A Alberti, F Tremolada, R Williams, A L Eddleston, G Realdi.   

Abstract

To investigate the possible mechanisms of liver cell injury in chronic non-A, non-B (NANB) hepatitis, peripheral blood lymphocytes (PBL) from 16 patients with chronic NANB hepatitis were incubated with autologous hepatocytes in a microcytotoxicity assay. Significant cytotoxicity was demonstrated in 11 patients. T-enriched lymphocytes exhibited significantly greater cytotoxicity than non-T enriched cells. No significant inhibition of cytotoxicity was observed following preincubation of the liver cells with either monoclonal or polyclonal anti-HBc, or monoclonal anti-HBs, or addition of either purified HBsAg or recombinant HBcAg to the culture, indicating that there was no detectable cross-reactivity in this system between hepatitis B virus (HBV) and NANB-associated antigen(s). Preincubation of the patients' hepatocytes with polyclonal IgG purified from a serum of a patient who recovered from an acute NANB hepatitis, did not significantly alter cytotoxicity. Liver cell surface-bound IgG was detected by immunofluorescence in only two of the patients, a finding consistent with existing evidence of poor antibody responses to both liver membrane and NANB-associated antigens. Control experiments using PBL from allogeneic normal donors exhibited normal cytotoxicity for the patients' hepatocytes supporting the hypothesis that antibody-dependent cell-mediated cytotoxicity (ADCC) is unlikely to play a significant role in this clinical setting.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082546      PMCID: PMC1577354     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Detection of a liver-membrane autoantibody in HBsAg-negative chronic active hepatitis.

Authors:  U Hopf; K H Meyer zum Büschenfelde; W Arnold
Journal:  N Engl J Med       Date:  1976-03-11       Impact factor: 91.245

2.  Antibody-dependent lymphocyte-mediated cytotoxicity. The nature of the effector cell and characterization of its fc receptor.

Authors:  L Simchowitz; P H Schur
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

3.  Changes in the solubility of immunoglobulins after fluorescent labeling and its influence on immunofluorescent techniques.

Authors:  W Arnold; H von Mayersbach
Journal:  J Histochem Cytochem       Date:  1972-12       Impact factor: 2.479

4.  T lymphocyte sensitization to HBcAg and T cell-mediated unresponsiveness to HBsAg in hepatitis B virus-related chronic liver disease.

Authors:  S Vento; J E Hegarty; A Alberti; C J O'Brien; G J Alexander; A L Eddleston; R Williams
Journal:  Hepatology       Date:  1985 Mar-Apr       Impact factor: 17.425

5.  Suppressor cell activity in viral and non-viral chronic active hepatitis.

Authors:  F Tremolada; G Fattovich; G Panebianco; G Ongaro; G Realdi
Journal:  Clin Exp Immunol       Date:  1980-04       Impact factor: 4.330

6.  Transmission of non-A, non-B hepatitis.

Authors:  J H Hoofnagle; R J Gerety; E Tabor; S M Feinstone; L F Barker; R H Purcell
Journal:  Ann Intern Med       Date:  1977-07       Impact factor: 25.391

7.  Circulating immune complexes in non-A, non-B hepatitis. Possible masking of viral antigen.

Authors:  J L Dienstag; A K Bhan; H J Alter; S M Feinstone; R H Purcell
Journal:  Lancet       Date:  1979-06-16       Impact factor: 79.321

8.  Lymphocyte cytotoxicity to autologous hepatocytes in HBsAg-negative chronic active hepatitis.

Authors:  G M Vergani; D Vergani; P J Jenkins; B Portmann; A P Mowat; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1979-10       Impact factor: 4.330

9.  Transmissible agent in non-A, non-B hepatitis.

Authors:  H J Alter; R H Purcell; P V Holland; H Popper
Journal:  Lancet       Date:  1978-03-04       Impact factor: 79.321

10.  Transmission of non-A, non-B hepatitis from man to chimpanzee.

Authors:  E Tabor; R J Gerety; J A Drucker; L B Seeff; J H Hoofnagle; D R Jackson; M April; L F Barker; G Pineda-Tamondong
Journal:  Lancet       Date:  1978-03-04       Impact factor: 79.321

View more
  7 in total

Review 1.  Chronic active hepatitis.

Authors:  P J Johnson; I G McFarlane
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

2.  Serum beta2-microglobulin in chronic hepatitis C.

Authors:  M Malaguarnera; S Restuccia; I Di Fazio; A M Zoccolo; B A Trovato; G Pistone
Journal:  Dig Dis Sci       Date:  1997-04       Impact factor: 3.199

3.  Correlation between serum HCV RNA and aminotransferase levels in patients with chronic HCV infection.

Authors:  M G Ghany; T M Chan; R Sanchez-Pescador; M Urdea; A S Lok
Journal:  Dig Dis Sci       Date:  1996-11       Impact factor: 3.199

4.  Lymphocyte subsets and beta 2-microglobulin expression in chronic hepatitis C/non-A, non-B. Effects of interferon-alpha treatment.

Authors:  R Wejstål; G Norkrans; O Weiland; R Schvarcz; D Fuchs; H Wachter; A Fryden; H Glaumann
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

5.  Expression rate of cytokine mRNA in the liver of chronic hepatitis C: comparison with chronic hepatitis B.

Authors:  R Fukuda; S Satoh; X T Nguyen; Y Uchida; N Kohge; S Akagi; S Ikeda; M Watanabe; S Fukumoto
Journal:  J Gastroenterol       Date:  1995-02       Impact factor: 7.527

Review 6.  Immunopathogenesis of Hepatitis C Virus Infection.

Authors:  David E Kaplan
Journal:  Gastroenterol Clin North Am       Date:  2015-08-13       Impact factor: 3.806

7.  Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha.

Authors:  J A Quiroga; J Martin; M Pardo; V Carreño
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.